Solvias, one of the world’s leading independent pharmaceutical testing and manufacturing companies, today announced that it has acquired Cergentis, based in Utrecht, Netherlands. The acquisition strengthens the Solvias platform of biological assays and solutions for cell and gene therapy.
According to pharmaceutical market intelligence provider Evaluate, global sales of cell and gene therapies are expected to accelerate at a compound annual growth rate of 63% through 2026. As more researchers use emerging genetic engineering techniques to develop new drugs and complex, they have advanced solutions needed to analyze their safety and effectiveness.
With the addition of Cergentis, Solvias is supporting the growing number of global pharmaceutical, biotechnology, and development contracting and manufacturing organizations developing genetically modified therapies with a broad platform of testing services, highlighted by
- a highly scientific team with advanced qualifications and in-depth knowledge of emerging genomic techniques and evolving regulatory requirements
- Patented genomic analysis technology that provides comprehensive data in a single experiment, enabling effective decision-making and designing research and development programs
- a global network serving customers on three continents
- personal support for individual genetic engineering applications, including cell and gene therapy, cell line development, and genetically modified models
- Expert knowledge of early-stage genomic sequencing to support one of the first steps in the R&D process
- High-contact support, including end-to-end logistics services, digital project management, and reporting capabilities to enable fast turnaround times
Joris Schuurmans, CEO of Cergentis, added:
“We are delighted to be part of a global leader that integrates our scientific expertise, innovation, and customer service. Solvias and Cergentis share a deep commitment to providing our customers with the highest quality solutions and support to get their products safely into the hands of patients in need.
With immediate effect, Mr. Schuurmans will join Solvia’s ‘leadership team’ and will continue to lead Cergentis’ activities.
Cergentis is Solvias’ second acquisition since partnering with healthcare investors Water Street Healthcare Partners and JLL Partners in 2020. The company has recruited industry leaders to join its board of directors and is running a program to significantly upgrade and improve the healthcare platform technology in the short term the infrastructure global expansion plans.